In keeping with the Gentris mission to promote excellence in pharmacogenomics testing, Gentris members are actively engaged in pharmacogenomic research with academic partners.
Scott Clark, VP of Global Scientific Operations at Gentris, and colleagues from the University of North Carolina at Chapel Hill, North Carolina State University, University of Michigan, Lineberger Comprehensive Cancer Center and the Moffitt Cancer Center recently published their results which examined the association of genetic variants with peripheral neuropathy in breast cancer patients treated with paclitaxel.
Paclitaxel is commonly used to treat breast tumors. It is understood that levels of toxicity differ significantly among patients and is dependent on drug exposure and genetics. In addition, the risk of developing sensory peripheral neuropathy is elevated in African-American patients. (more…)
Read the Article:
The Impact of Storage Conditions on DNA Derived from Buccal Swabs
Date: March 27 – 28, 2014
Location: London, UK
February 20, 2014
Morrisville, N.C. – Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics solutions, biomarker testing and biorepository services, announced today the addition of Dr. Heath Knight as vice president, corporate development and Mr. Joseph Kessler, as chief operating officer. These two executives join the executive leadership team as the company anticipates its next phase of growth.
Amelia Wall Warner, PharmD, RPh
CEO and President, Gentris Corporation
I have had the great fortune of working for several managers during my professional career who set a high bar for expectations around corporate ethics and integrity. Having been raised by parents with high work ethic and unflinching integrity (coupled with a healthy fan appreciation for Jimmy Stewart films), I have always believed that with hard work, unwavering honesty, and a continual focus on quality and integrity, I will be able to help the companies that employ me achieve high commercial success.
I recently assumed the CEO role at Gentris after spending much of my career in large pharma. Though I worked with many service providers during my tenure in pharma, joining Gentris has given me an even greater appreciation of the service business. I feel so fortunate to be surrounded by individuals who work harder than the competition, achieve the highest quality results, and always insist on following the ethical business path. This has become even more meaningful to me as I continue to learn about the competitive landscape in this business. I have become increasingly aware of the lengths to which some of our competitors will go to win contracts. I am not sure if this is fueled by difficult economic times, changing client focus, or not enough voluntary viewings of It’s a Wonderful Life. It would have been demoralizing if I had not found a core team at Gentris excited about a transparent and principled approach to this service sector. (more…)
Date: November 7 – 9, 2013
Location: Boston, Massachusetts
Date: November 5 – 6, 2013
Location: Cambridge, Massachusetts
Drug discovery is a long, costly process with a high attrition rate, and a personalized medicine strategy is needed to improve clinical outcomes. Identifying the subclass of patients who is likely to respond to drugs and developing biomarkers for patient stratification before recruitment for clinical trials would improve efficacy and response rates. Cambridge Healthtech Institute’s Inaugural Biomarkers for Patient Stratification meeting will explore the integration of biomarkers and companion diagnostics into drug development, case studies of using biomarkers to guide clinical decision making, molecular profiling approaches and their impact on clinical development, as well as personalized medicine initiatives at big pharma.
Date: November 4 – 5, 2013
Location: Indianapolis, Indiana
Today, biospecimen collections are used by multiple research groups for varying research aims, from basic research through clinical trials. A well-managed biobank is a critical prerequisite for high-quality biological research. The proper collection, processing, storage and tracking of biospecimens are critical components allowing researchers to better link molecular and clinical information. Thus, by necessity, biobanking is both a science and a business. Cambridge Healthtech Institute’s Fifth Annual Leaders in Biobanking: Maximizing Your Investment in Biospecimens addresses both the business and science of biobanking, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today’s cutting-edge research.
October 4, 2013
Morrisville, N.C. – Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, announced today that Gentris founder, Michael Murphy, and leading cancer pharmacogenomics expert, Dr. Howard McLeod, have joined the Board of Directors.
“I am excited to welcome Michael Murphy and Dr. Howard McLeod to the Board of Directors,” said Tim Gupton, Gentris Chairman. “They bring a tremendous wealth of scientific, industry, and regulatory experience to Gentris and will provide invaluable guidance on strategic opportunities as we drive a new phase of company growth. The Board looks forward to working with Gentris’ senior management to build upon our 12-year history of success in pharmacogenomics and biobanking and to develop cutting-edge solutions that enable clients to capitalize on the promise of personalized medicine.”
At Gentris, we believe in providing the highest level of quality services to meet our customer’s needs. From our CAP Accredited biorepository, to our CLIA regulated laboratory, we strive to be the leader in pharmacogenomics solutions.